Zhiqun Zhang

Dr. Zhiqun Zhang


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2019 in Respiratory Research
Verified
Journal Article
Open access
PDF file
JLJing Li
Jing Li
XLXiaoxia Li
Xiaoxia Li
XHXianmei Huang
Xianmei Huang
ZZZhiqun Zhang
Zhiqun Zhang
Noninvasive high-frequency oscillatory ventilation (nHFOV), a relatively new modality, is gaining popularity despite scarce evidence. This meta-analysis was designed to evaluate the efficacy and safety of nHFOV as respiratory support in premature infants. We searched MEDLINE, EMBASE, CINAHL, and Cochrane CENTRAL from inception of the database to January 2019. All published randomized controlled trials (RCTs) evaluating the effect of nHFOV therapy with nasal continuous positive airway pressure (nCPAP) or biphasic nCPAP (BP-CPAP) in newborns for respiratory support were included. All meta-analyses were performed using Review Manager 5.3. A total of 8 RCTs involving 463 patients were included. The meta-analysis estimated a lower risk of intubation (relative risk = 0.50, 95% confidence interval of 0.36 to 0.70) and more effective clearance of carbon dioxide (weighted mean difference = − 4.61, 95% confidence interval of − 7.94 to − 1.28) in the nHFOV group than in the nCPAP/BP-CPAP group. Our meta-analysis of RCTs suggests that nHFOV, as respiratory support in preterm infants, significantly remove carbon dioxide and reduce the risk of intubation compared with nCPAP/BP-CPAP. The appropriate parameter settings for different types of noninvasive high-frequency ventilators, the effect of nHFOV in extremely preterm infants, and the long-term safety of nHFOV need to be assessed in large trials.

24 April 2019 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
HHHui Hong
Hui Hong
XLXiao-Xia Li
Xiao-Xia Li
JLJing Li
Jing Li
ZZZhiqun Zhang
Zhiqun Zhang
Background: As a noninvasive respiratory support mode, high flow nasal cannula (HFNC) is widely used in preterm infants at neonatal care units. HFNC is often used as an alternative to nasal continuous positive airway pressure (NCPAP) for initial or postextubation respiratory support. The purpose of this meta-analysis is to evaluate and compare the efficacy and safety of HFNC and NCPAP for respiratory support in preterm infants. Methods: We searched PubMed, Web of Science, Embase, Cochrane Library, Clinicaltrials.gov, Controlled-trials.com, Google Scholar, VIP, and Wang Fang for articles from their inception to December 2018. All published randomized controlled trials (RCTs) evaluating and comparing the effects of HFNC and NCPAP therapy for primary respiratory support in newborns were included. All meta-analyses were performed using Review Manager 5.3. Results: In total, 21 RCTs involving 2886 preterm infants were included. The results of the meta-analysis revealed the following: 1) for primary respiratory support, the rates of treatment failure at trial entry were similar between HFNC and CPAP (relative risk 1.03, 95% confidence interval 0.79–1.33), and HFNC had reduced nasal trauma (p < 0.00001); and 2) for respiratory support after extubation, CPAP was associated with a lower likelihood of treatment failure than HFNC (relative risk 1.23, 95% confidence interval 1.01–1.50). The incidences of nasal trauma and pneumothorax in the HFNC group were significantly lower than that in the CPAP group (p < 0.0001 and p = 0.03). Serious adverse events did not significantly differ. Conclusions: HFNC had effects similar to those of CPAP regarding the failure of initial respiratory support in premature infants and was associated with reduced nasal trauma compared to CPAP. Following extubation, CPAP had fewer treatment failures than HFNC, but CPAP had a significantly increased rate of nasal trauma and pneumothorax. Further studies are needed to clarify the potential benefits of HFNC as primary respiratory support in extremely low birth weight or extremely preterm infants.

3 November 2020 in Molecular Medicine
Verified
Journal Article
Open access
PDF file
DWDi Wang
Di Wang
HHHui Hong
Hui Hong
XLXiao-Xia Li
Xiao-Xia Li
JLJing Li
Jing Li
ZZZhiqun Zhang
Zhiqun Zhang
Background: The incidence of bronchopulmonary dysplasia (BPD), a chronic lung disease of newborns, has been paradoxically rising despite medical advances. Histone deacetylase 3 (Hdac3) has been reported to be a crucial regulator in alveologenesis. Hence, this study aims to investigate the mechanism of Hdac3 in the abnormal pulmonary angiogenesis and alveolarization of BPD. Methods: A hyperoxia-induced BPD model of was developed in newborn mice, and primary lung fibroblasts were isolated from adult mice. Hdac3 was knocked out in vivo and knocked down in vitro, while microRNA (miR)-17 was downregulated in vivo and in vitro to clarify their roles in abnormal pulmonary angiogenesis and alveolarization. Mechanistic investigations were performed on the interplay of Hdac3, miR-17-92 cluster, enhancer of zeste homolog 1 (EZH1), p65 and placental growth factor (Pgf). Results: Hdac3 was involved in abnormal alveolarization and angiogenesis in BPD mice. Further, the expression of the miR-17-92 cluster in BPD mice was downregulated by Hdac3. miR-17 was found to target EZH1, and Hdac3 rescued the inhibited EZH1 expression by miR-17 in lung fibroblasts. Additionally, EZH1 augmented Pgf expression by recruiting p65 thus enhancing the progression of BPD. Hdac3 augmented the recruitment of p65 in the Pgf promoter region through the miR-17/EZH1 axis, thus enhancing the transcription and expression of Pgf, which elicited abnormal angiogenesis and alveolarization of BPD mice. Conclusions: Altogether, the present study revealed that Hdac3 activated the EZH1-p65-Pgf axis through inhibiting miR-17 in the miR-17-92 cluster, leading to accelerated abnormal pulmonary angiogenesis and alveolarization of BPD mice.

15 December 2017 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
ZZZhiqun Zhang
Zhiqun Zhang
YZYing Zhong
Ying Zhong
XHXian-Mei Huang
Xian-Mei Huang
LDlizhong du
lizhong du
Uncertainly prevails with regard to the use of inhalation or instillation steroids to prevent bronchopulmonary dysplasia in preterm infants. The meta-analysis with sequential analysis was designed to evaluate the efficacy and safety of airway administration (inhalation or instillation) of corticosteroids for preventing bronchopulmonary dysplasia (BPD) in premature infants. We searched MEDLINE, EMBASE, CINAHL, and Cochrane CENTRAL from their inceptions to February 2017. All published randomized controlled trials (RCTs) evaluating the effect of airway administration of corticosteroids (AACs) vs placebo or systemic corticosteroid in prematurity were included. All meta-analyses were performed using Review Manager 5.3. Twenty five RCTs retrieved (n = 3249) were eligible for further analysis. Meta-analysis and trial sequential analysis corrected the 95% confidence intervals estimated a lower risk of the primary outcome of BPD (relative risk 0.71, adjusted 95% confidence interval 0.57–0.87) and death or BPD (relative risk 0.81, adjusted 95% confidence interval 0.71–0.97) in AACs group than placebo and it is equivalent for preventing BPD than systemic corticosteroids. Moreover, AACs fail to increasing risk of death compared with placebo (relative risk 0.90, adjusted 95% confidence interval 0.40–2.03) or systemic corticosteroids (relative risk 0.81, 95% confidence interval 0.62–1.06). Our findings suggests that AACs (especially instillation of budesonide using surfactant as a vehicle) are an effective and safe option for preventing BPD in preterm infants. Furthermore, the appropriate dose and duration, inhalation or instillation with surfactant as a vehicle and the long-term safety of airway administration of corticosteroids needs to be assessed in large trials.

1 January 2014 in Disease Markers
Verified
Journal Article
Open access
PDF file
KWKeyi Wang
Keyi Wang
XHXianmei Huang
Xianmei Huang
HLHui Lu
Hui Lu
ZZZhiqun Zhang
Zhiqun Zhang
Objectives. To evaluate the predictive characteristics of KL-6 and CC16 for bronchopulmonary dysplasia (BPD) in preterm infants, either independently or in combination.Study Design. This prospective cohort study was performed from 2011 to 2013 with preterm neonates of gestational age ≤32 weeks and birth weight ≤1500 g. Serum KL-6 and CC16 levels were determined 7 and 14 days after birth.Results. Seventy-three preterm infants were studied. BPD was identified in 24 of these infants. After adjusting for potential confounders, serum KL-6 concentrations were found to be elevated in BPD infants at both time points relative to non-BPD infants, while serum CC16 concentrations were lower at 14 days. At both 7 d and 14 d of life the predictive power of KL-6 levels exceeded that of CC16 (area under receiver operating characteristic curve: at 7 d, 0.91 cf. 0.73,P=0.02; at 14 d, 0.95 cf. 0.85,P=0.05). The combination of these markers enhanced the sensitivity further.Conclusions. Serum KL-6 levels higher than 79.26 ng/mL at 14 days postpartum in preterm infants predict the occurrence of BPD. CC16 was less predictive than KL-6 at this time point, but KL-6 and CC16 together enhanced the prediction.

1 May 2021 in Translational Pediatrics
Verified
Journal Article
Open access
PDF file
JLJing Li
Jing Li
HXHejie Xia
Hejie Xia
LYLin Ye
Lin Ye
XLXiaoxia Li
Xiaoxia Li
ZZZhiqun Zhang
Zhiqun Zhang
Background: Pulmonary hemorrhage is a potentially fatal event especially for preterm infants, which can lead to serious complications and even death. Many risk factors have been associated with the development of massive pulmonary hemorrhage. However, there is still no effective strategy to prevent massive pulmonary hemorrhage. The purpose of this study is to explore prediction model and survival strategies for massive pulmonary hemorrhage in premature infants. Methods: In this retrospective study, we included all premature infants with birth weight <1,500 g who were hospitalized in our neonatal intensive care unit (NICU) between January 01 2010 and December 31 2019. Results: Of 599 preterm infants, 51 developed massive pulmonary hemorrhage. The logistic regression analysis showed that patent ductus arteriosus [odds ratio (OR) =11.4, 95% confidence interval (CI): 4.79–27.0, P<0.0001], coagulopathy (OR =6.56, 95% CI: 2.83–15.2, P<0.0001), and 10-minute Apgar Score (OR =0.52, 95% CI: 0.37–0.73, P=0.0001) were risk factors for massive pulmonary hemorrhage. Whether or not surfactant is used, the positive predictive value of combined patent ductus arteriosus and coagulopathy for predicting massive pulmonary hemorrhage was 68.9% and 70.4%, respectively. Of the 51 preterm infants with massive pulmonary hemorrhage, 25 died and 26 survived. The survivors group had higher positive end-expiratory pressure compared with the deceased group after the onset of massive pulmonary hemorrhage. After adjusting for potential risk factors, the multiple logistic regression analysis showed that higher positive end-expiratory pressure levels are closely related to survival. Conclusions: Patent ductus arteriosus combined with coagulopathy has a high predictive value for massive pulmonary hemorrhage. Higher positive end-expiratory pressure levels may reduce mortality in massive pulmonary hemorrhage.